The tTG tests are usually done to help doctors diagnose celiac disease. A Tissue Transglutaminase (tTG) test is used as part of an evaluation for certain autoimmune conditions, most notably celiac disease. An autoimmune disease can occur when the body’s immune system mistakenly perceives a nonthreatening substance. In the case of people with celiac disease, gluten (a protein found in wheat, barley, rye, and oats) is seen as a foreign invader and is attacked by the immune system.
This immune system response in celiac disease also involves the production of antibodies directed against an enzyme normally present in the intestines called Tissue Transglutaminase (tTG). In celiac disease, the body produces two types of antibodies that attack tTG: immunoglobulin A (IgA) and immunoglobulin G (IgG). Measuring the IgA form of tTG antibody in the blood is more useful in detecting celiac disease because it’s made in the small intestine, where gluten causes inflammation and irritation in sensitive people. Levels of the IgG form of tTG antibody, on the other hand, are less specific to celiac disease, but may still be useful in diagnosing the condition in people who are unable to make normal amounts of IgA antibodies.
Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/824
Major Key Players
- Mayo Clinic,
- Quest Diagnostics,
- Coeliac UK,
- SQI Diagnostics,
- Trinity Biotech,
- Zedira GmbH,
- Demeditec Diagnostics GmbH
According to a recent study report published by the Market Research Future, The global market of Tissue Transglutaminase Test is been increasing. The market is expected to grow at a rapid pace during the forecast period (2017 – 2027). The Tissue Transglutaminase Test Market is forecasted to demonstrate a spectacular growth by 2027, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2027).
Globally the market for Tissue Transglutaminase Test is increasing rapidly and the main reason for this is the increasing incidences of celiac disease. This disease is highly spreading due to gluten (a protein found in wheat, barley, rye, and oats). It is also found that the celiac disease spreads due to genetics. The growth for Tissue Transglutaminase Test market is increasing due to the introduction of DNA test for HLA markers DQ2 and DQ8 which improve the ability to identify those patients at risk for celiac disease. Almost all the patients suffering from celiac disease carry the HLA markers hence there is high growth for Tissue Transglutaminase Test market worldwide.
This test is considered a safe procedure. However, as with many medical tests, some problems can occur with having blood drawn, such as: fainting or feeling lightheaded, hematoma (blood accumulating under the skin causing a lump or bruise) and pain associated with multiple punctures to locate a vein
Test the market data and market information presented through more than 50 market data tables and figures spread over 124 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Tissue Transglutaminase Test Market Research Report – Forecast to 2027”.
The tTG Test market appears to be highly competitive and fragmented owing to the presence of several large and small key players accounting for a substantial market share. Tissue Transglutaminase Test kit manufacturers invest substantially in to R&D to develop technically advance kits. Well established players incorporate acquisition, collaboration, partnership, expansion, product & technology launch in order to gain competitive advantage in this market and to maintain their market position.
Globally, North America is leading market Tissue Transglutaminase Test. This is mainly because of the increasing growth rate of celiac disease in humans. Countries like U.S and Canada are the leading Tissue Transglutaminase Test market in North America. Europe is one of the emerging markets for Tissue Transglutaminase Test. In Europe, countries like Germany followed by France and UK are the leading market for Tissue Transglutaminase Tests. This is because the celiac disease is spread in most of the European descent countries. In Europe this disease is mainly found in children aging from 2.5 to 15 years i.e. on an average 3 to 13 per 1000 children. Due to which the market for Tissue Transglutaminase Test is growing rapidly in Europe.
Browse Statistical Report
Europe Insulin Pump Market is projected to grow at a CAGR of 8.7% and is expected to reach US$ 2,784.5 million by 2023. In Europe Insulin Pump Market, Germany accounted for the largest market share in 2016.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
+1 646 845 9312